Articles tagged ‘dronedarone’

“Hypertension is the most prevalent risk factor leading to the development of atrial fibrillation (AF), the most common arrhythmia” according to Dr I Grundvold, University of Oslo.

Sanofi-aventis has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending to grant a marketing authorization in the European Union for Multaq® (dronedarone – 400mg Tablets).

Use of the antiarrhythmic drug dronedarone significantly reduced the risk of hospitalisation due to cardiovascular events or death in patients with paroxysmal or persistent atrial fibrillation or flutter in the ATHENA trial. New data are now available on trial patients with heart failure.